Verified factor-similar pair

USVM vs VIOG

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB UMD
Similarity score
91
Near substitute

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • VIOG has the higher backtested relative Sharpe (1.225 vs 1.046).
  • VIOG has the lower published fee (0.10% vs 0.29%).
  • USVM is cheaper on dividend valuation (79 vs 126, where 100 is each fund's historical median).
  • USVM has the stronger regression fit (adjusted R-squared 0.962 vs 0.954).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

USVM

VictoryShares US Small Mid Cap Value Momentum ETF
SMB UMD
Adj. R2
0.962
Rel. Sharpe
1.046
Mkt beta
0.97
AUM
US$1.5B
MER
0.29%
Valuation
79

VIOG

Vanguard S&P Small-Cap 600 Growth ETF
SMB UMD
Adj. R2
0.954
Rel. Sharpe
1.225
Mkt beta
0.98
AUM
US$894M
MER
0.10%
Valuation
126

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
USVM
+0.79
|t|
+16.5
VIOG
+0.91
|t|
+24.2
diff -0.12
HML
USVM
+0.20
|t|
+4.8
VIOG
+0.07
|t|
+2.0
diff +0.13
RMW
USVM
+0.15
|t|
+2.9
VIOG
+0.14
|t|
+3.3
diff +0.01
CMA
USVM
+0.01
|t|
+0.2
VIOG
-0.03
|t|
-0.5
diff +0.04
UMD
USVM
+0.14
|t|
+4.2
VIOG
+0.16
|t|
+6.0
diff -0.02

Why This Pair Matches

Exposure level
89
Exposure shape
99
Mkt beta diff
0.01
Rel. Sharpe diff
0.179

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

USVM fund page VIOG fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.